Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations. J of Skin. 2025;9(1):s524. doi:10.25251/skin.9.supp.524